Do analysts recommend EXOZ or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EXOZ or QCLS more profitable?

Mymd Pharmaceuticals' return on equity of -76.40% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Mymd Pharmaceuticals N/A -76.40% -35.10%

Does the media favor EXOZ or QCLS?

In the previous week, eXoZymes and eXoZymes both had 1 articles in the media. eXoZymes' average media sentiment score of 0.85 beat Mymd Pharmaceuticals' score of 0.00 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend QCLS or RNXT?

RenovoRx has a consensus target price of $8.50, indicating a potential upside of 698.12%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts clearly believe RenovoRx is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Does the media favor QCLS or RNXT?

In the previous week, RenovoRx had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for RenovoRx and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 0.00 equaled RenovoRx'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ATHE or QCLS?

Alterity Therapeutics currently has a consensus price target of $13.00, indicating a potential upside of 188.57%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, ATHE or QCLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A

Is ATHE or QCLS more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Mymd Pharmaceuticals N/A -76.40% -35.10%

Does the media favor ATHE or QCLS?

In the previous week, Alterity Therapeutics had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for Alterity Therapeutics and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 0.00 beat Alterity Therapeutics' score of -0.39 indicating that Mymd Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate QCLS or FTH?

Sensei Biotherapeutics has a consensus target price of $54.90, suggesting a potential upside of 118.11%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sensei Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83

Which has preferable earnings and valuation, QCLS or FTH?

Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Is QCLS or FTH more profitable?

Mymd Pharmaceuticals' return on equity of -76.40% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -76.40% -35.10% Sensei Biotherapeutics N/A -83.59% -256.50%

Does the media favor QCLS or FTH?

In the previous week, Sensei Biotherapeutics had 6 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 7 mentions for Sensei Biotherapeutics and 1 mentions for Mymd Pharmaceuticals. Sensei Biotherapeutics' average media sentiment score of 0.88 beat Mymd Pharmaceuticals' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate QCLS or DYAI?

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 201.51%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media refer more to QCLS or DYAI?

In the previous week, Dyadic International had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for Dyadic International and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 0.00 beat Dyadic International's score of -0.10 indicating that Mymd Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Mymd Pharmaceuticals (QCLS) Competitors

$2.91 -0.02 (-0.68%)

As of 12:59 PM Eastern

Compare

QCLS vs. EXOZ, RNXT, ATHE, FTH, and DYAI

Should you buy Mymd Pharmaceuticals stock or one of its competitors? MarketBeat compares Mymd Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mymd Pharmaceuticals include eXoZymes (EXOZ), RenovoRx (RNXT), Alterity Therapeutics (ATHE), Sensei Biotherapeutics (FTH), and Dyadic International (DYAI).

How does Mymd Pharmaceuticals compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Mymd Pharmaceuticals (NASDAQ:QCLS) are related small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 72.4% of eXoZymes shares are held by company insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, eXoZymes and eXoZymes both had 1 articles in the media. eXoZymes' average media sentiment score of 0.85 beat Mymd Pharmaceuticals' score of 0.00 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

eXoZymes has higher revenue and earnings than Mymd Pharmaceuticals. eXoZymes is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	698.64	-$9.16M	-$1.14	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mymd Pharmaceuticals' return on equity of -76.40% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

eXoZymes has a beta of 2.93, meaning that its stock price is 193% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market.

Summary

eXoZymes beats Mymd Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to RenovoRx?

Mymd Pharmaceuticals (NASDAQ:QCLS) and RenovoRx (NASDAQ:RNXT) are related small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

RenovoRx has higher revenue and earnings than Mymd Pharmaceuticals. RenovoRx is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
RenovoRx	$1.12M	42.84	-$11.17M	-$0.33	N/A

RenovoRx has a consensus target price of $8.50, indicating a potential upside of 698.12%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts clearly believe RenovoRx is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, RenovoRx had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for RenovoRx and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 0.00 equaled RenovoRx'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mymd Pharmaceuticals has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, RenovoRx has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by insiders. Comparatively, 9.4% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Mymd Pharmaceuticals has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Mymd Pharmaceuticals' return on equity of -76.40% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
RenovoRx	-823.98%	-135.03%	-101.92%

Summary

RenovoRx beats Mymd Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Mymd Pharmaceuticals (NASDAQ:QCLS) are related small-cap companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Alterity Therapeutics' return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

Alterity Therapeutics currently has a consensus price target of $13.00, indicating a potential upside of 188.57%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Alterity Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market.

In the previous week, Alterity Therapeutics had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for Alterity Therapeutics and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 0.00 beat Alterity Therapeutics' score of -0.39 indicating that Mymd Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Alterity Therapeutics beats Mymd Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Sensei Biotherapeutics?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Sensei Biotherapeutics (NASDAQ:FTH) are related small-cap companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, Sensei Biotherapeutics had 6 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 7 mentions for Sensei Biotherapeutics and 1 mentions for Mymd Pharmaceuticals. Sensei Biotherapeutics' average media sentiment score of 0.88 beat Mymd Pharmaceuticals' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sensei Biotherapeutics has a consensus target price of $54.90, suggesting a potential upside of 118.11%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Mymd Pharmaceuticals' return on equity of -76.40% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Mymd Pharmaceuticals has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market.

Summary

Sensei Biotherapeutics beats Mymd Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Dyadic International?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Dyadic International (NASDAQ:DYAI) are related small-cap companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Comparatively, 20.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Dyadic International had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for Dyadic International and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 0.00 beat Dyadic International's score of -0.10 indicating that Mymd Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyadic International has higher revenue and earnings than Mymd Pharmaceuticals. Dyadic International is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
Dyadic International	$3.09M	11.73	-$7.36M	-$0.23	N/A

Mymd Pharmaceuticals has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 201.51%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Mymd Pharmaceuticals has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Mymd Pharmaceuticals' return on equity of -76.40% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Summary

Dyadic International beats Mymd Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Mymd Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QCLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QCLS vs. The Competition

Export

Metric	Mymd Pharmaceuticals	Technology Hardware, Storage & Peripherals Industry	Technology Sector	NASDAQ Exchange
Market Cap	$12.14M	$107.50B	$29.79B	$12.94B
Dividend Yield	N/A	1.71%	2.76%	10.01%
P/E Ratio	-0.14	37.56	81.95	25.55
Price / Sales	N/A	124.69	598.63	91.90
Price / Cash	N/A	23.54	47.90	49.40
Price / Book	0.56	8.20	9.27	6.10
Net Income	-$11.63M	$3.10B	$662.76M	$348.05M
7 Day Performance	15.94%	9.94%	6.87%	4.87%
1 Month Performance	-24.42%	0.03%	-1.21%	-2.01%
1 Year Performance	N/A	98.47%	152.44%	21.16%

Mymd Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QCLS Mymd Pharmaceuticals	0.0996 of 5 stars	$2.91 -0.7%	N/A	N/A	$12.14M	N/A	N/A	6	News Coverage Positive News Gap Up
EXOZ eXoZymes	0.4851 of 5 stars	$4.60 +4.4%	N/A	-53.5%	$40.53M	N/A	N/A	29	News Coverage
RNXT RenovoRx	3.6526 of 5 stars	$0.94 +4.8%	$8.50 +803.1%	-14.0%	$40.46M	$1.12M	N/A	6	News Coverage Upcoming Earnings
ATHE Alterity Therapeutics	2.9051 of 5 stars	$4.47 +0.6%	$13.00 +191.2%	-15.7%	$39.37M	N/A	N/A	10
FTH Sensei Biotherapeutics	4.3088 of 5 stars	$28.82 -0.4%	$54.75 +90.0%	N/A	$38.82M	N/A	N/A	40	News Coverage Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QCLS) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. EXOZ, RNXT, ATHE, FTH, and DYAI

How does Mymd Pharmaceuticals compare to eXoZymes?

Summary

How does Mymd Pharmaceuticals compare to RenovoRx?

Summary

How does Mymd Pharmaceuticals compare to Alterity Therapeutics?

Summary

How does Mymd Pharmaceuticals compare to Sensei Biotherapeutics?

Summary

How does Mymd Pharmaceuticals compare to Dyadic International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. EXOZ, RNXT, ATHE, FTH, and DYAI

How does Mymd Pharmaceuticals compare to eXoZymes?

Do insiders & institutionals have more ownership in EXOZ or QCLS?

Does the media favor EXOZ or QCLS?

Which has higher earnings & valuation, EXOZ or QCLS?

Do analysts recommend EXOZ or QCLS?

Is EXOZ or QCLS more profitable?

Which has more volatility and risk, EXOZ or QCLS?

Summary

How does Mymd Pharmaceuticals compare to RenovoRx?

Which has stronger valuation and earnings, QCLS or RNXT?

Do analysts recommend QCLS or RNXT?

Does the media favor QCLS or RNXT?

Which has more risk and volatility, QCLS or RNXT?

Do institutionals & insiders have more ownership in QCLS or RNXT?

Is QCLS or RNXT more profitable?

Summary

How does Mymd Pharmaceuticals compare to Alterity Therapeutics?

Is ATHE or QCLS more profitable?

Do analysts rate ATHE or QCLS?

Which has more volatility & risk, ATHE or QCLS?

Does the media favor ATHE or QCLS?

Which has stronger earnings and valuation, ATHE or QCLS?

Do institutionals and insiders believe in ATHE or QCLS?

Summary

How does Mymd Pharmaceuticals compare to Sensei Biotherapeutics?

Does the media favor QCLS or FTH?

Do analysts rate QCLS or FTH?

Which has preferable earnings and valuation, QCLS or FTH?

Do institutionals and insiders hold more shares of QCLS or FTH?

Is QCLS or FTH more profitable?

Which has more volatility & risk, QCLS or FTH?

Summary

How does Mymd Pharmaceuticals compare to Dyadic International?

Do insiders & institutionals hold more shares of QCLS or DYAI?

Does the media refer more to QCLS or DYAI?

Which has better valuation & earnings, QCLS or DYAI?

Which has more volatility and risk, QCLS or DYAI?

Do analysts rate QCLS or DYAI?

Is QCLS or DYAI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools